Possible Interaction: Glucose and Rosiglitazone

“ Rosiglitazone reduced insulin concentrations by 30% (P < 0.001) and glucose by 14% (P < 0.00001).”

“Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.”

“In HepG2, the peroxisome proliferator-activated receptor (PPAR) agonist, rosiglitazone , reduced the glucose production by 72.9%.”

“The results showed that high glucose significantly reduced cell viability through generation of ROS via activation of PKC, which was inhibited by RSG.”

“And rosiglitazone therapy decreased plasma vaspin levels through glucose and insulin sensitivity regulation.”

“Addition of rosiglitazone significantly reduced glycosylated haemoglobin (HbA1c) (p < 0.0005) and fasting glucose (p < 0.05) and improved FMD (p < 0.005).”

“… rosiglitazone treatment showed a significant increase of serum sialic acid concentration (…+/-5.56 mg/dl, p=0.01) along with glucose (112+/-6.2 vs. 88.35+/-6.31 mg/dl, p<0.04) and … vs. 170.6+/-15.1mg/dl, p<0.01) as compared to control subjects.”

“BACKGROUND Although rosiglitazone may offer vascular benefits beyond lowering glucose , recently, concern has been raised that this drug may paradoxically increase cardiovascular risk.”

“ResultsBoth metformin and rosiglitazone treatments reduced significantly the high levels of glucose and HbA1c, and slightly improved lipid profile during 2 months.”

“It was found that Rosiglitazone significantly stimulated cell glucose utilization with negligible cytotoxicity at the concentration of 10(-5) M. CONCLUSION The simplicity and efficiency of the optimized method has been proven in this study.”